Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
US-12180196-B2 · Dec 31, 2024 · US
US9115115B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9115115-B1 |
| Application number | US-201514666812-A |
| Country | US |
| Kind code | B1 |
| Filing date | Mar 24, 2015 |
| Priority date | Aug 19, 2014 |
| Publication date | Aug 25, 2015 |
| Grant date | Aug 25, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
3-(3-chloro-1H-pyrazol-1-yl)pyridine is prepared by cyclizing 3-hydrazinopyridine-•dihydrochloride with a dialkyl maleate to provide an alkyl 5-oxo-2-(pyridin-3-yl)pyrazolidine-3-carboxylate, by chlorinating to provide an alkyl 3-chloro-1-(pyridin-3-yl)-4,5-dihydro-1H-pyrazole-5-carboxylate, by oxidizing to provide an alkyl 3-chloro-1-(pyridin-3-yl)-1H-pyrazole-5-carboxylate, by converting the ester to the carboxylic acid by hydrolysis to provide 3-chloro-1-(pyridin-3-yl)-1H-pyrazole-5-carboxylic acid hydrochloride, and by removing the carboxylic acid by a decarboxylation reaction.
Opening claim text (preview).
What is claimed is: 1. A process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b), which comprises a) treating 3-hydrazinopyridine•dihydrochloride with a dialkyl maleate wherein R represents (C 1 -C 4 ) alkyl, in a (C 1 -C 4 ) aliphatic alcohol at a temperature of about 25° C. to about 100° C. in the presence of an alkali metal (C 1 -C 4 ) alkoxide to provide an alkyl 5-oxo-2-(pyridin-3-yl)pyrazolidine-3-carboxylate (10a) wherein R is as previously defined; b) treating the alkyl 5-oxo-2-(pyridin-3-yl)pyrazolidine-3-carboxylate (10a) with a chlorinating reagent in an inert organic solvent at a temperature of about 25° C. to about 100° C. to provide an alkyl 3-chloro-1-(pyridin-3-yl)-4,5-dihydro-1H-pyrazole-5-carboxylate (10b) wherein R is as previously defined; c) treating the alkyl 3-chloro-1-(pyridin-3-yl)-4,5-dihydro-1H-pyrazole-5-carboxylate (10b) with an oxidant in an inert organic solvent at a temperature of about 25° C. to about 100° C. to provide an alkyl 3-chloro-1-(pyridin-3-yl)-1H-pyrazole-5-carboxylate (10c) wherein R is as previously defined; d) treating the alkyl 3-chloro-1-(pyridin-3-yl)-1H-pyrazole-5-carboxylate (10c) with aqueous hydrochloric acid at a temperature of about 25° C. to about 100° C. to provide 3-chloro-1-(pyridin-3-yl)-1H-pyrazole-5-carboxylic acid hydrochloride (10d) and e) treating 3-chloro-1-(pyridin-3-yl)-1H-pyrazole-5-carboxylic acid hydrochloride with copper(II) oxide in a polar aprotic solvent at a temperature of about 80° C. to about 140° C. 2. The process of claim 1 in which for step a) the dialkyl maleate is diethyl maleate, the (C 1 -C 4 ) aliphatic alcohol is ethanol and the alkali metal (C 1 -C 4 ) alkoxide is sodium ethoxide. 3. The process of claim 1 in which for step b) the chlorinating reagent is phosphoryl chloride and the inert organic solvent is acetonitrile. 4. The process of claim 1 in which for step c) the oxidant is manganese (IV) oxide and the inert organic solvent is acetonitrile. 5. The process of claim 1 in which for step e) the polar aprotic solvent is N,N′-dimethylformamide. 6. A molecule having the following structure, wherein R represents (C 1 -C 4 ) alkyl. 7. A molecule having the following structure, wherein R represents (C 1 -C 4 ) alkyl.
directly linked by a ring-member-to-ring-member bond · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.